The Huntsville active pharmaceutical ingredient site will produce small molecule synthetic and peptide medicines, including Lilly's oral GLP-1 orforglipron.
The agreement reportedly will strengthen both companies' sterile drug product manufacturing portfolios through the integration of fill-finish and packaging technologies.
